Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

PHASE4CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

March 24, 2022

Primary Completion Date

December 10, 2024

Study Completion Date

December 10, 2024

Conditions
HyperkalaemiaChronic Kidney Disease
Interventions
DRUG

Sodium Zirconium Cyclosilicate (SZC)

"White to grey crystalline powder for oral suspension in 5 g sachets. Each sachet will be labeled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement.~Label text will be translated into local language."

DRUG

Local standard of care

Local SoC in the country to be used as per local label

Trial Locations (28)

2820

Research Site, Bonheiden

3000

Research Site, Leuven

9006

Research Site, Burgos

11207

Research Site, Algeciras

27100

Research Site, Pavia

28007

Research Site, Madrid

28040

Research Site, Madrid

28702

Research Site, San Sebastián de los Reyes

28905

Research Site, Getafe

37007

Research Site, Salamanca

41009

Research Site, Seville

42270

Research Site, Saint-Priest-en-Jarez

43125

Research Site, Parma

45600

Research Site, Talavera de la Reina

49022

Research Site, Zamora

57530

Research Site, Ars-Laquenexy

70120

Research Site, Bari

71122

Research Site, Foggia

07103

Research Site, Annonay

06000

Research Site, Nice

5602 ZA

Research Site, Eindhoven

04009

Research Site, Almería

06080

Research Site, Badajoz

08907

Research Site, Barcelona

DN2 5LT

Research Site, Doncaster

HU10 7AZ

Research Site, Hull

M6 8HD

Research Site, Salford

SG1 4AB

Research Site, Stevenage

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY